{
    "id": "424e41da-dc3a-4605-8358-57db40ab8eb1",
    "indications": {
        "text": "intuniv\u00ae indicated treatment attention deficit hyperactivity disorder ( adhd ) monotherapy adjunctive therapy stimulant medications [ ( 14 ) ] .",
        "doid_entities": [
            {
                "text": "attention deficit hyperactivity disorder (DOID:1094)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1094"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "recommended dose : 1 mg 7 mg ( 0.05 0.12 mg/kg target weight based dose range ) daily morning evening based response tolerability ( 2.2 ) . begin dose 1 mg daily adjust increments 1 mg/week ( 2.2 ) . crush , chew break tablets swallowing ( 2.1 ) . administer high-fat meals , increased exposure ( 2.1 ) . substitute immediate-release guanfacine tablets mg-per-mg basis , differing pharmacokinetic profiles ( 2.3 ) . switching immediate-release guanfacine , discontinue treatment titrate intuniv directed ( 2.3 ) . discontinuing , taper dose decrements 1 mg every 3 7 days avoid rebound hypertension ( 2.5 ) .",
        "doid_entities": [
            {
                "text": "hypertension (DOID:10763)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_10763"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "intuniv supplied 1 mg , 2 mg , 3 mg , 4 mg strength extended-release tablets 100 count bottles . 1 mg 2 mg 3 mg 4 mg color white/off-white white/off-white green green shape round caplet round caplet debossment ( top/bottom ) 503 / 1 mg 503 / 2 mg 503 / 3 mg 503 / 4 mg ndc number 54092-513-02 54092-515-02 54092-517-02 54092-519-02",
    "adverseReactions": "intuniv contraindicated patients history hypersensitivity reaction intuniv inactive ingredients , products containing guanfacine . rash pruritus reported .",
    "ingredients": [
        {
            "name": "GUANFACINE HYDROCHLORIDE",
            "code": "PML56A160O",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5559"
        },
        {
            "name": "HYPROMELLOSE 2208 (15000 MPA.S)",
            "code": "Z78RG6M2N2",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "CROSPOVIDONE (120 .MU.M)",
            "code": "68401960MK"
        },
        {
            "name": "METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER (1:1)",
            "code": "74G4R6TH13",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_25219"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "GLYCERYL DIBEHENATE",
            "code": "R8WTH25YS2",
            "drugbank_id": "https://go.drugbank.com/drugs/DB13038"
        },
        {
            "name": "FUMARIC ACID",
            "code": "88XHZ13131",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_18012"
        }
    ],
    "organization": "Takeda Pharmaceuticals America, Inc.",
    "name": "Intuniv",
    "effectiveTime": "20250508",
    "indications_original": "INTUNIV\u00ae is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications [see Clinical Studies (14)].",
    "contraindications_original": "Recommended dose: 1 mg to 7 mg (0.05 to 0.12 mg/kg target weight based dose range) once daily in the morning or evening based on clinical response and tolerability ( 2.2 ). Begin at a dose of 1 mg once daily and adjust in increments of no more than 1 mg/week ( 2.2 ). Do not crush, chew or break tablets before swallowing ( 2.1 ). Do not administer with high-fat meals, because of increased exposure ( 2.1 ). Do not substitute for immediate-release guanfacine tablets on a mg-per-mg basis, because of differing pharmacokinetic profiles ( 2.3 ). If switching from immediate-release guanfacine, discontinue that treatment and titrate with INTUNIV as directed ( 2.3 ). When discontinuing, taper the dose in decrements of no more than 1 mg every 3 to 7 days to avoid rebound hypertension ( 2.5 ).",
    "warningsAndPrecautions_original": "INTUNIV is supplied in 1 mg, 2 mg, 3 mg, and 4 mg strength extended-release tablets in 100 count bottles.\n                  \n                     \n                     \n                     \n                     \n                     \n                     \n                        \n                           \n                           1 mg\n                           2 mg\n                           3 mg\n                           4 mg\n                        \n                     \n                     \n                        \n                           \n                              Color\n                           \n                           White/off-white\n                           White/off-white\n                           Green\n                           Green\n                        \n                        \n                           \n                              Shape\n                           \n                           Round\n                           Caplet\n                           Round\n                           Caplet\n                        \n                        \n                           \n                              Debossment(top/bottom)\n                           \n                           503 / 1 mg\n                           503 / 2 mg\n                           503 / 3 mg\n                           503 / 4 mg\n                        \n                        \n                           \n                              NDC number\n                           \n                           54092-513-02\n                           54092-515-02\n                           54092-517-02\n                           54092-519-02",
    "adverseReactions_original": "INTUNIV is contraindicated in patients with a history of a hypersensitivity reaction to INTUNIV or its inactive ingredients, or other products containing guanfacine. Rash and pruritus have been reported.",
    "drug": [
        {
            "name": "Intuniv",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5559"
        }
    ]
}